Logo

Genentech Will Use Dharmacon s RNAi Technology for Drug Discovery

Jan 21, 2005

NEW YORK, Jan. 21 (GenomeWeb News) - Genentech will use Dharmacon's RNAi technology in its drug-discovery research, Dharmacon said today.

 

Under the agreement, Dharmacon will supply Genentech with siRNA reagents, including its Human Druggable Genome library.

 

Dharmacon, a subsidiary of Fisher Scientific International, is located in Lafayette, Colo.

Breaking News
The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.